

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/072486 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61K 31/502 (2006.01)
A61K 45/06 (2006.01) A61K 39/395 (2006.01)
A61K 33/243 (2019.01) A61P 35/00 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/048613

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

26 September 2024 (26.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/585,585 26 September 2023 (26.09.2023) US
63/674,151 22 July 2024 (22.07.2024) US
63/691,804 06 September 2024 (06.09.2024) US

(71) Applicant: **PROFOUND BIO US CO.** [US/US]; 14241
NE Woodinville-Duvall Rd., #228, Woodinville, WA 98072
(US).

(72) Inventors: **ZHAO, Baiteng**; c/o ProfoundBio US Co.,
14241 NE Woodinville-Duvall Rd., #228, Woodinville, WA
98072 (US). **HAN, Tae**; c/o ProfoundBio US Co., 14241
NE Woodinville-Duvall Rd., #228, Woodinville, WA 98072
(US).

(74) Agent: **REMILLARD, Jane, E.** et al.; Nelson Mullins Ri-
ley & Scarborough LLP, One Financial Center, Suite 3500,
Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: DOSAGE OF ANTIBODY DRUG CONJUGATE RINATABART SESUTECAN

(57) Abstract: The present invention relates to a method of treating solid tumor by administering to a human subject an antibody-drug conjugate (ADC) comprising an antibody to FOLR1 conjugated via a hydrophilic linker to exatecan. The ADC is administered at a dosage of between 40 mg/m² and 200 mg/m². In one embodiment, the ADC is conjugate rinatabart sesutecan (Rina-S). When administered at specified dosages and schedules, the ADC can reduce tumors size and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The ADC may be used in combination with other anti-cancer drugs.

WO 2025/072486 A1